

Purified Human Pancreatic Islets CIT Enzyme Solution: SERVA Enzymes Proportional Units Collagenase & Neutral Protease – Standard Operating Procedure of the NIH Clinical Islet Transplantation Consortium

The NIH CIT Consortium Chemistry Manufacturing Controls Monitoring Committee:

J. Ansite, A.N. Balamurugan, B. Barbaro, J. Battle, D. Brandhorst, J. Cano, X. Chen, S. Deng, D. Feddersen, A. Friberg, T. Gilmore, J.S. Goldstein, E. Holbrook, A. Khan, T. Kin, J. Lei, E. Linetsky, C. Liu, X. Luo, K. McElvaney, Z. Min, J. Moreno, D. O’Gorman, K.K. Papas, G. Putz, C. Ricordi, G. Szot, T. Templeton, L. Wang, J.J. Wilhelm, J. Willits, T. Wilson, X. Zhang

The NIH CIT Consortium

Emory University: J. Avila, B. Begley, J. Cano, S. Carpentier, E. Holbrook, J. Hutchinson, C.P. Larsen, J. Moreno, M. Sears, N.A. Turgeon, D. Webster

Massachusetts General Hospital: S. Deng, J. Lei, J.F. Markmann

NIAID: N.D. Bridges, C.W. Czarniecki, J.S. Goldstein, G. Putz, T. Templeton, T. Wilson

NIDDK: T.L. Eggerman

Northwestern University: P. Al-saden, J. Battle, X. Chen, A. Hecyk, H. Kissler, X. Luo, M. Molitch, N. Monson, E. Stuart, A. Wallia, L. Wang, S. Wang, X. Zhang

University of Alberta, Edmonton: D. Bigam, P. Campbell, P. Dinyari, T. Kin, N. Kneteman, J. Lyon, A. Malcolm, D. O’Gorman, C. Onderka, R. Owen, R. Pawlick, B. Richer, S. Rosichuk, D. Sarman, A. Schroeder, P.A. Senior, A.M.J. Shapiro, L. Toth, V. Toth, W. Zhai

University of California–San Francisco: K. Johnson, J. McElroy, A.M. Posselt, M. Ramos, T. Rojas, P.G. Stock, G. Szot

University of Illinois, Chicago: B. Barbaro, J. Martellotto, J. Oberholzer, M. Qi, Y. Wang

University of Iowa (Data Coordinating Center): L. Bayman, K. Chaloner, W. Clarke, J.S. Dillon, C. Diltz, G.C. Doelle, D. Ecklund, D. Feddersen, E. Foster, L. G. Hunsicker, C. Jasperson, D-E Lafontant, K. McElvaney, T. Neill-Hudson, D. Nollen, J. Qidwai, H. Riss, T. Schwieger, J. Willits, J. Yankey

University of Miami: R. Alejandro, A.C. Corrales, R. Faradji, T. Froud, A.A. Garcia, E. Herrada, H. Ichii, L. Inverardi, N. Kenyon, A. Khan, E. Linetsky, J. Montelongo, E. Peixoto, K. Peterson, C. Ricordi, J. Szust, X. Wang

- University of Minnesota:** M.H. Abdulla, J. Ansite, A.N. Balamurugan, M.D. Bellin, M. Brandenburg, T. Gilmore, J. V. Harmon, B.J. Hering, R. Kandaswamy, G. Loganathan, K. Mueller, K.K. Papas, J. Pedersen, J.J. Wilhelm, J. Witson
- University of Pennsylvania:** C. Dalton-Bakes, H. Fu, M. Kamoun, J. Kearns, Y. Li, C. Liu, E. Luning-Prak, Y. Luo, E. Markmann, Z. Min, A. Naji, M. Palanjian, M. Rickels, R. Shlansky-Goldberg, K. Vivek, A.S. Ziae
- University of Wisconsin:** L. Fernandez, D.B. Kaufman, L. Zitur
- Uppsala University:** D. Brandhorst, A. Friberg, O. Korsgren

Supported by grants from the National Institute of Allergy and Infectious Diseases and the National Institute for Diabetes and Digestive and Kidney Diseases.

- At Emory University, U01AI089317.
- At Northwestern University, U01AI089316.
- At the University of Alberta, Edmonton: U01AI065191.
- At the University of California, San Francisco, U01DK085531.
- At the University of Illinois, Chicago, 5U01DK070431-10.
- At the University of Iowa, U01DK070431.
- At the University of Miami, U01DK070460.
- At the University of Minnesota, U01AI065193.
- At the University of Pennsylvania, U01DK070430.
- At Uppsala University, U01AI065192.

In addition, the study was supported by the following GCRC and CTSA awards:

- At Emory University: UL1TR000454.
- At Northwestern University: 5UL1RR025741 and 8UL1TR000150.
- At the University of California, San Francisco, UL1TR000004.
- At the University of Illinois, Chicago, UL1TR000050.
- At the University of Miami: 1UL1TR000460.
- At the University of Minnesota: 5M01-RR000400 and UL1TR000114.
- At the University of Pennsylvania: UL1TR000003.

Address correspondence to: Camillo Ricordi MD, Chairman, CIT Steering Committee,
ricordi@miami.edu

To cite this article

Purified Human Pancreatic Islets CIT Enzyme Solution: SERVA Enzymes Proportional Units Collagenase & Neutral Protease – Standard Operating Procedure of the NIH Clinical Islet Transplantation Consortium

CellR4 2015; 3 (1): e1342

DAIT, NIAID, NIH**SOP
ATTACHMENT**Document No.
3106, B11Revision Date
03Effective Date
25 October 2010Supersedes Date
02 June 2009

Page 1 of 3

Document Title:

**PURIFIED HUMAN PANCREATIC ISLETS
CIT ENZYME SOLUTION – SERVA ENZYMES
PROPORTIONAL UNITS COLLAGENASE & NEUTRAL PROTEASE**

Manufacturing Site: _____ Date: _____

1.0 Hanks' Balanced Salt Solution, 1X +10 u/mL Heparin

1.1 Materials:

Material	Source	Lot #	Expiration Date	Quantity Required	Quantity Used
Hanks' Balanced Salt Solution, 1X				1 L	L
Heparin Sodium Injection USP, Preservative Free		_____ Units/mL		_____ mL (See below)	mL

1.2 Procedure

Prepare 1 liter of HBSS, 1X with 10 u/mL of heparin. Calculate the amount of heparin to be added to the liter of HBSS, 1X to produce 10 u/mL heparin.

$$\frac{10 \text{ u/mL in media} \times 1,000 \text{ mL}}{\text{u/mL in heparin solution}} = \text{mL heparin solution to use}$$

$$\frac{10 \text{ u/mL in media} \times 1,000 \text{ mL}}{\text{u/mL heparin}} = \text{mL}$$

Calculated by: _____

Date: _____

Verified by: _____

Date: _____

Document No. 3106, B11	Revision Date 03	Effective Date 25 October 2010	Supersedes Date 02 June 2009	Page 2 of 3
---------------------------	---------------------	-----------------------------------	---------------------------------	-------------

Document Title: PURIFIED HUMAN PANCREATIC ISLETS, CIT ENZYME SOLUTION – SERVA ENZYMES, PROPORTIONAL UNITS COLLAGENASE & NEUTRAL PROTEASE

2.0 Enzyme Solution

2.1 Materials:

Material	Source	Lot #	Expiration Date	Quantity Required	Quantity Used
Hanks' Balanced Salt Solution, 1X + 10 u/mL heparin				~330 to ~480 mL	mL
Collagenase NB 1 <input type="checkbox"/> GMP Grade <input type="checkbox"/> Premium Grade	SERVA			Calculated below	mL
Calcium Chloride USP (Dihydrate) (CaCl ₂ 2 H ₂ O)				0.52 g	g
1 M HEPES				35 mL	mL
Neutral Protease NB <input type="checkbox"/> GMP Grade <input type="checkbox"/> Premium Grade	SERVA			Calculated below	mL
Sterile Water for Injection				10 mL	mL

2.1 Based on the Cannulated Pancreas Weight (MPBR Section 5.8) and the table below, determine the volume of this solution to make and the amount of enzymes to use.

CANNULATED PANCREAS WEIGHT (g)	CIT ENZYME SOLUTION VOLUME (mL)	COLLAGENASE (UNITS)	NEUTRAL PROTEASE (UNITS)
< 100	350	1600	200
100 – 125	400	1829	229
126 – 150	450	2057	257
> 150*	500	2286	286

*For a pancreas > 150 g, there is an option to divide the pancreas into two portions and digest these separately.

Cannulated Pancreas Weight (MPBR Section 5.8): _____ g

CIT Enzyme Solution Volume to be prepared: _____ mL

Collagenase: _____ Units

Neutral Protease: _____ Units

2.2 Collagenase NB 1 Reconstitution

2.2.1 **ABOUT 45 MINUTES BEFORE PERfusion** add 40 mL of HBSS, 1X + heparin to one vial of Collagenase NB 1.

2.2.2 Let collagenase dissolve at 2°C – 8°C (about 30 minutes). Swirl gently occasionally.

2.3 Calcium Chloride 11 mM

2.3.1 Add 0.52 g Calcium Chloride USP (dihydrate) to a 50 mL sterile conical tube.

2.3.2 Add 35 mL of 1 M HEPES to the 50 mL conical tube and mix to dissolve.

2.3.3 Filter the CaCl₂ solution through a 0.22 micron filter into a sterile 500 mL bottle.

Islets Lot Number: _____

Document No. 3106, B11	Revision Date 03	Effective Date 25 October 2010	Supersedes Date 02 June 2009	Page 3 of 3
---------------------------	---------------------	-----------------------------------	---------------------------------	-------------

Document Title: PURIFIED HUMAN PANCREATIC ISLETS, CIT ENZYME SOLUTION – SERVA ENZYMES, PROPORTIONAL UNITS COLLAGENASE & NEUTRAL PROTEASE

- 2.4 Calculate volume of Collagenase NB-1 solution to use in order to have the determined (Section 2.1, above) number of units:

$$\frac{40 \text{ mL/vial} \times \text{Collagenase Units Required}}{\text{Collagenase Units/vial}} = \text{mL Collagenase NB-1 to use}$$

$$\frac{40 \text{ mL/vial} \times \text{ }}{\text{Units/vial}} = \text{ mL}$$

- 2.5 Add the calculated volume of dissolved Collagenase NB-1 to the sterile 500 mL bottle.
- 2.6 Calculate the volume of Neutral Protease NB solution to use in order to have the determined (Section 2.1, above) number of units:

$$\frac{10 \text{ mL/vial} \times \text{Neutral Protease Units Required}}{\text{Neutral Protease Units/vial}} = \text{mL Neutral Protease to use}$$

$$\frac{10 \text{ mL/vial} \times \text{ }}{\text{Units/vial}} = \text{ mL}$$

- 2.7 Neutral Protease NB Reconstitution
Add 10 mL of Sterile Water for Injection to one vial of Neutral Protease and mix to dissolve.
- 2.8 Q.S the 500 mL bottle to the volume determined in Section 2.1, above, minus the volume of Neutral Protease NB solution to be added, with HBSS, 1X + heparin. Swirl gently to mix.
- 2.9 Label the bottle with:
- “CIT Enzyme Solution”
 - “Volume prepared _____ mL”
 - “Store at 2°C to 8°C”
 - Date and Time Prepared (*mmddyyyy, 24 hour clock*)
 - Expiration Date and Time (one half hour after preparation) (*mmddyyyy, 24 hour clock*)
 - Initials of the person who prepared the solution
- 2.10 Add the calculated volume of dissolved Neutral Protease NB to the sterile 500 mL bottle immediately before the start of perfusion.

Prepared by: _____

Date: _____

Reviewed by: _____

Date: _____